Dr Reddy's bets on generic semaglutide, biosimilars

Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3y6PozZ
via IFTTT

Read More

Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?

Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% rise in prescriptions over six months. Prices have fallen from over Rs 1 lakh to around Rs 30,000 per cycle, but hospital stocking practices could determine whether patients benefit from lower costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RCM4mj0
via IFTTT

Read More

One Science Nutrition: Building a science-led approach to sports nutrition

One Science Nutrition was co-founded by Aman and Aniket Vachher to create credible sports nutrition products. The brand aims to cater to evolving consumer expectations around product quality and transparency. Their product range includes various supplements that support diverse fitness goals and health benefits. Future strategies involve leveraging artificial intelligence to enhance consumer experiences and product discovery. The founders emphasize maintaining core values while pursuing growth in the nutrition industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/90xr2IG
via IFTTT

Read More

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson reported results from an early-stage trial of their prostate cancer drug JNJ-6143. The trial involved patients with advanced prostate cancer who had undergone multiple treatments. Results showed 77% of patients experienced a significant drop in PSA levels after treatment. Additionally, 69% of patients demonstrated confirmed partial or complete tumor response through imaging. Common side effects included nausea and elevated cholesterol levels, with one patient discontinuing treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GY9MseC
via IFTTT

Read More

States urged to enforce ban on reuse of single-use medical devices

The Directorate General of Health Services has issued a directive to prohibit the reuse of single-use medical devices. Violations by some private hospitals have raised concerns regarding patient safety and regulatory compliance. The directive specifically targets misuse in high-stakes medical fields such as cardiology and neurosurgery. Monitoring and enforcement of compliance by healthcare establishments have been mandated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dTYQWjS
via IFTTT

Read More

Jubilant Pharmova eyes $150 million through rupee debt sale, bankers say

Jubilant Pharmova plans to raise around Rs 14 billion ($150 million) through a three-year rupee bond offering to fund capital expenditure and refinance project-related liabilities at overseas subsidiaries. The proposed issuance, rated AA+ by India Ratings, could take place before the end of next month, according to two merchant bankers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5Ax9oDs
via IFTTT

Read More

From nasal delivery to sterile injectables: Biodeal Pharmaceuticals’ expansion plans

Biodeal Pharmaceuticals is set to broaden its horizons with a state-of-the-art sterile injectables plant in Himachal Pradesh. This venture will notably elevate its production capacities and diversify its contract development and manufacturing services. Biodeal is committed to fortifying existing partnerships with clients leveraging its innovative nasal and oral drug formulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3u5xN89
via IFTTT

Read More